Neurocrine Biosciences has received FDA approval for a new therapy called Crenessity for congenital adrenal hyperplasia (CAH). CAH is an inherited disorder affecting cortisol production, leading to hormone imbalances that can be fatal. Crenessity is a non-steroidal drug that blocks hormone secretion and reduces the need for high doses of steroids, which have many side effects. The drug is approved for adults and children and is expected to be priced within the range of orphan drugs. Analysts project significant revenue for the company, with potential global sales reaching $1.47 billion. Neurocrine also acquired Diurnal Group to expand its presence in endocrine disorders.
Source link
Neurocrine Lands FDA Nod for First New Treatment in Decades for Rare Endocrine Disorder
